Longitudinal immune reconstitution profiling suggests anti-viral protection after transplantation with omidubicel: A phase III sub-study.-Gamida Cell Ltd
Gamida Cell announced that two oral presentations and a poster presentation highlighting Gamida Cell’s investigational product candidate omidubicel at the 2023 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT).
The title is: "Longitudinal Immune Reconstitution Profiling Suggests Anti-Viral Protection after Transplantation with Omidubicel: A Phase III Substudy", Abstract Number: 84. Lead Author: Roei Mazor, M.D., Ph.D.; Head of the Clinic of Histiocytic Neoplasms at Assuta Medical Center and Medical Director at Gamida Cell.
Highlights: New data on peripheral blood lymphocyte counts measured in correlation with time to neutrophil and platelet engraftment in omidubicel transplanted and standard cord blood transplanted patients. Seven days post-transplant, omidubicel transplanted patients showed a statistically significant correlation between CD3+/CD4+ T cell counts and time to neutrophil engraftment. Similar correlations were noted between CD3+/CD8+/CD19+ cell counts and time to platelet engraftment. Patients transplanted with standard cord blood showed no such correlations at Day 7 post-transplant, and only began to show correlations starting at 14 days post-transplant. Data support past findings that omidubicel stimulates a faster immune response than standard cord blood and may also explain the lower incidence of serious bacterial, fungal and viral infections for omidubicel transplanted patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins